Welcome back, everyone. We hope you had a nice long weekend that was refreshing and relaxing. Now, though, the time has come to resume the routine - yes, those meetings and deadlines loom once again. So please join us for a much-needed cup of stimulation as we plow through the to-do list. And here is another invite: our Dec. 9 webinar on the FDA's Accelerated Approval program (see here). Meanwhile, here are a few tidbits to get you going. Have a great day...
FDA Questions Glaxo's Avodart For Prostate Cancer Risk (Dow Jones)
Merck Scraps Trial Of Once-Daily AIDS Pill (Dow Jones)
Glaxo Signs Deal With Russia's Binnopharm (The Moscow Times)
Pfizer & Protalix File Gaucher Disease Med In Europe (PharmaTimes)
Ranbaxy May Start Selling Generic Aricept (Bloomberg News)
Cardinal Health Buys Chinese Drug Distributor (MarketWatch)
KV Pharma Given Extra Time To Pay Fines (St. Louis Business Journal)
EMA To Revise Guidance On GMP Tech Transfer To CMOs (OutsourcingPharma)
Vietnam Arrests Pharma Exec For Securities Fraud (Bloomberg News)
Sudbury Hopes To Become Canadian Pharma Hub (Northern Life)
Pfizer Begins Work On Nigerian Medical Facility (Next)
FDA Extends Review for Merck KGgA MS Pill (Bloomberg News)
Pfizer Donates Remediated Land For Park Use (The Morning Call)
2 Comments
Ranbaxy has the six month exclusivity on Aricept. I expect that they will charge egregious prices until the other ANDA holders jump in May. By this time next year expect generic Aricept to sell for about 20% of current price.
Even on a handheld, that's quite a good looking sunrise! Belated thanks for starting the week off with 'a light touch!'